These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9036122)

  • 1. [Plasmapheresis and immunopathogenetic aspects of toxic epidermal necrolysis].
    Hermes B; Haas N; Henz BM
    Hautarzt; 1996 Oct; 47(10):749-53. PubMed ID: 9036122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis.
    Paquet P; Paquet F; Al Saleh W; Reper P; Vanderkelen A; Piérard GE
    Am J Dermatopathol; 2000 Oct; 22(5):413-7. PubMed ID: 11048976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stevens-Johnson syndrome/toxic epidermal necrolysis].
    Watanabe H; Iijima M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():336-40. PubMed ID: 18072345
    [No Abstract]   [Full Text] [Related]  

  • 4. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
    Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
    J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse intraepidermal deposition of immunoreactants on direct immunofluorescence: a clue to the early diagnosis of epidermal necrolysis.
    King T; Helm TN; Valenzuela R; Bergfeld WF
    Int J Dermatol; 1994 Sep; 33(9):634-6. PubMed ID: 8002159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺ T cells.
    Yang C; Mosam A; Mankahla A; Dlova N; Saavedra A
    J Am Acad Dermatol; 2014 Jun; 70(6):1096-102. PubMed ID: 24629995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
    White JC; Appleman S
    Pediatrics; 2014 Oct; 134(4):e1194-8. PubMed ID: 25246624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.
    Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS
    Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.
    Worswick S; Cotliar J
    Dermatol Ther; 2011; 24(2):207-18. PubMed ID: 21410610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmapheresis, Intravenous Immunoglobulins, and Autologous Serum Eyedrops in the Acute Eye Complications of Toxic Epidermal Necrolysis.
    Pinna A; Nuvoli E; Blasetti F; Posadinu MA; Boscia F
    Eur J Ophthalmol; 2017 Nov; 27(6):658-663. PubMed ID: 28362052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of the Active Treatments for Toxic Epidermal Necrolysis.
    Kinoshita Y; Saeki H
    J Nippon Med Sch; 2017; 84(3):110-117. PubMed ID: 28724844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythema multiforme and toxic epidermal necrolysis: a comparative study.
    Paquet P; Piérard GE
    Am J Dermatopathol; 1997 Apr; 19(2):127-32. PubMed ID: 9129696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases.
    Koštál M; Bláha M; Lánská M; Koštálová M; Bláha V; Štepánová E; Malý J
    J Clin Apher; 2012; 27(4):215-20. PubMed ID: 22407895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidermal necrolysis: mechanisms of keratinocyte apoptosis].
    Roujeau JC; Gélard K; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):188-91. PubMed ID: 16457761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Lerner LH; Qureshi AA; Reddy BV; Lerner EA
    J Invest Dermatol; 2000 Jan; 114(1):196-9. PubMed ID: 10620138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Pathogenesis of Toxic Epidermal Necrolysis.
    Kinoshita Y; Saeki H
    J Nippon Med Sch; 2016; 83(6):216-222. PubMed ID: 28133001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.
    Nassif A; Bensussan A; Dorothée G; Mami-Chouaib F; Bachot N; Bagot M; Boumsell L; Roujeau JC
    J Invest Dermatol; 2002 Apr; 118(4):728-33. PubMed ID: 11918724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.